Forsta AP Fonden Invests $798,000 in BioNTech SE Sponsored ADR $BNTX

Forsta AP Fonden acquired a new position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 8,379 shares of the company’s stock, valued at approximately $798,000.

Other large investors have also recently added to or reduced their stakes in the company. Larson Financial Group LLC increased its stake in BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the period. Huntington National Bank increased its stake in BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after buying an additional 380 shares during the period. Tower Research Capital LLC TRC increased its stake in BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares during the period. Hantz Financial Services Inc. increased its stake in BioNTech by 100.3% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,146 shares of the company’s stock worth $113,000 after buying an additional 574 shares during the period. Finally, Jones Financial Companies Lllp increased its stake in BioNTech by 50.6% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,199 shares of the company’s stock worth $118,000 after buying an additional 403 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Trading Down 0.8%

Shares of NASDAQ:BNTX opened at $88.45 on Thursday. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The company’s 50 day moving average is $94.50 and its two-hundred day moving average is $99.07. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. The company has a market cap of $22.37 billion, a PE ratio of -15.04 and a beta of 1.32.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The firm had revenue of $1.06 billion during the quarter. Equities analysts predict that BioNTech SE Sponsored ADR will post -4.71 earnings per share for the current fiscal year.

BioNTech announced that its Board of Directors has approved a share buyback plan on Thursday, May 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

BNTX has been the topic of several recent research reports. Morgan Stanley upped their target price on shares of BioNTech from $125.00 to $126.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Canaccord Genuity Group cut their target price on shares of BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Wells Fargo & Company cut their target price on shares of BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Truist Financial raised shares of BioNTech to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Berenberg Bank cut their target price on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $129.56.

Insider Activity at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. This represents a 11.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.20% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.